Bausch Health Companies Inc. BHC
NYSE · XNYS · stock · Pharmaceutical Preparations
Chart by TradingView
6/9
Piotroski F — financial health
-0.23
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $10.3B | $157.0M | — | $1.0B | $377.0M |
| 2024 | $9.6B | -$46.0M | — | $1.3B | -$322.0M |
| 2023 | $8.8B | -$592.0M | — | $817.0M | -$82.0M |
| 2022 | $8.1B | -$225.0M | — | -$946.0M | $260.0M |
| 2021 | $8.4B | -$948.0M | — | $1.2B | -$34.0M |
| 2020 | $8.0B | -$560.0M | — | $809.0M | $605.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| WECHSLER AMY B | director | 2026-05-22 | Grant | 45,871 | — |
| ROBERTS EIRY | director | 2026-05-22 | Grant | 45,871 | — |
| POWER ROBERT N | director | 2026-05-22 | Grant | 45,871 | — |
| Paulson John | director | 2026-05-22 | Grant | 45,871 | — |
| LEUNG SANDRA | director | 2026-05-22 | Grant | 45,871 | — |
| Lee Frank D. | director | 2026-05-22 | Grant | 45,871 | — |
| KAVANAGH SARAH B | director | 2026-05-22 | Grant | 45,871 | — |
| GOETTLER MICHAEL | director | 2026-05-22 | Grant | 45,871 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.23 (distress)
- Working capital / assets 0.075
- Retained earnings / assets -0.367
- EBIT / assets 0.069
- Equity / liabilities 0.015
Source: SEC EDGAR filings · CIK 0000885590 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.